Bibliography
- de Galan BE, Perkovic V, Ninomiya T, ADVANCE Collaborative Group. Lowering blood pressure reduces cardiovascular events in type 2 diabetes. J Am Soc Nephrol 2009;20:883-92
- Cravedi P, Ruggenenti P, Remuzzi G. Which antihypertensive drugs are the most nephroprotective and why? Expert Opin Pharmacother 2010;11:2651-63
- Mancia G, Laurent S, Agabiti-Rosei E. European Society of Hypertension. Reappraisal of European guidelines on hypertension management. A European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-58
- Yusuf S, Teo KK, Pogue J, ONTARGET Trial Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358(15):1547-59
- Hemmelgarn HR, Manns BJ, Lloyd A, Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010;303:423-9
- Haller H, Sadayoshi I, Izzo JL, Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011;364:907-17
- Mancia G, De Backer G, Dominiczak A, 2007 Guidelines for the Management of Arterial Hypertension: the task force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
- Pugsley MK. The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes. Proc West Pharmacol Soc 2005;48:35-8
- Grassi G, Quarti-Trevano F, Dell'Oro R, The “J curve” problem revisited: old and new findings. Curr Hypertens Rep 2010;12:290-5
- Messerli FH, Mancia G, Conti CR, Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006;144:884-93
- Cushman WC, Evans GW, Byington RP, for the ACCORD Study Group. Effect of intensive blood pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-85
- Imai E, Ito S, haneda M, Olmesartan reducing incidence of endstage renal disease in diabetic nephropathy trial (ORIENT): rationale and study design. Hypertens Res 2006;29:703-9